Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS
Dimethyl fumarate (DMF), recently approved as an oral immunomodulatory treatment for relapsing-remitting multiple sclerosis (MS), metabolizes to monomethyl fumarate (MMF) which crosses the blood–brain barrier and has demonstrated neuroprotective effects in experimental studies. We postulated that MM...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Springer Berlin Heidelberg
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503882/ |